Technical Service Need help? Our team of experienced experts is here for you with full support.
AKA-237
Revumenib Citrate
Cat. No.
AKA-237
CAS No.
2761046-45-9
MF
C32H47FN6O4S.C6H8O7.H2O
MW
840.96
Revumenib citrate is the citrate salt form of the small molecule revumenib (SNDX-5613), a selective inhibitor of the menin–MLL protein–protein interaction used as a chemical tool for mechanistic studies of protein–protein interactions.
Advanced Equipments & Extensive Production Expertise
Commercial Manufacturing
Stable Quality
Customization Supporting
Technical Service 
86-28-85159085 
info@aktin.com Technical Data
Description
Documents
Storage and Shipping
References
Product Name
Revumenib Citrate
CAS No.
2761046-45-9
MF
C32H47FN6O4S.C6H8O7.H2O
MW
840.96
Specification
98.0%–102.0% on anhydrous basis
Research Area
Cytochrome P450 CYP3A4 inhibitor
Disclaimer
This product is intended solely for scientific research or regulatory filing purposes. We do not provide products or services to individuals, please strictly comply with all applicable laws, regulations, and the committed use. Use for any other purpose is strictly prohibited.
Description
Revumenib citrate is the citrate salt form of the small molecule revumenib (SNDX-5613), a selective inhibitor of the menin–MLL protein–protein interaction used as a chemical tool for mechanistic studies of protein–protein interactions. Packing: 10mg, 20mg, 50mg, 100mg, 500mg, 1g, 5g, 10g, 1kg Availability: In stock
Documents
Can't find the right version? Our team of experienced experts is here for you with full support.Contact Us
Storage and Shipping
Store in a cool & dry place, keep away from strong light and heat.
References
[1]. MedChemExpress (MCE) Product Catalog. Revumenib Citrate (CAS 2761046-45-9). Available at: https://www.medchemexpress.com/revumenib.html. Accessed 2026.
Related Products
* Some statements have not been evaluated by national authorities. * Some products are not intended to diagnose, treat, cure, or prevent any disease. * For literature supporting, please contact us directly.
